Stock listing
BOATS:STTK Shattuck Labs, Inc. Stock
US listing (BOATS) of Shattuck Labs, Inc. · home listing NASDAQ:STTK
Follow Shattuck Labs, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:STTK
$4.46 USD -0.01 (-0.2%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:STTK
- Day range
- $4.42 – $4.68 USDNov 20, 2026
- Volume
- 1.03M sharesNov 20, 2026
- Market cap
- $454.2M USDAt the close on Nov 20, 2026 · price × 101.8M shares outstanding
- 52-week range
- $1.89 – $8.33 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.99M USDMedian day 956,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:STTK · Home | $4.46 USD | -0.01 (-0.2%) | 1,031,130 | $4.48 | $4.68 | $4.42 | $4.47 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:STTK · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.46 | -0.01 | -0.2% | $4.48 | $4.68 | $4.42 | 1,031,130 | |
| $4.47 | -0.12 | -2.6% | $4.58 | $4.775 | $4.338 | 2,075,290 | |
| $4.59 | -0.07 | -1.5% | $4.755 | $4.755 | $4.44 | 785,679 | |
| $4.66 | +0.01 | +0.2% | $4.61 | $4.82 | $4.52 | 1,337,963 | |
| $4.65 | -0.16 | -3.3% | $4.79 | $4.831 | $4.50 | 775,896 | |
| $4.81 | -0.24 | -4.8% | $5.03 | $5.03 | $4.695 | 1,315,891 | |
| $5.05 | +0.20 | +4.1% | $4.89 | $5.095 | $4.86 | 984,409 | |
| $4.85 | -0.14 | -2.8% | $4.92 | $5.10 | $4.79 | 734,966 | |
| $4.99 | +0.37 | +8.0% | $4.70 | $5.05 | $4.535 | 1,271,396 | |
| $4.62 | +0.13 | +2.9% | $4.49 | $4.76 | $4.38 | 1,148,332 | |
| $4.49 | -0.66 | -12.8% | $5.11 | $5.11 | $4.44 | 1,427,676 | |
| $5.15 | -0.32 | -5.9% | $5.60 | $5.72 | $5.10 | 870,574 | |
| $5.47 | +0.15 | +2.8% | $5.38 | $5.56 | $5.24 | 849,982 | |
| $5.32 | -0.24 | -4.3% | $5.59 | $5.64 | $5.22 | 651,578 | |
| $5.56 | -0.16 | -2.8% | $5.67 | $5.74 | $5.36 | 951,430 | |
| $5.72 | -0.085 | -1.5% | $5.85 | $5.95 | $5.57 | 676,326 | |
| $5.805 | +0.035 | +0.6% | $5.72 | $5.94 | $5.65 | 799,175 | |
| $5.77 | +0.23 | +4.2% | $5.55 | $5.81 | $5.48 | 699,500 | |
| $5.54 | +0.05 | +0.9% | $5.53 | $5.68 | $5.46 | 706,094 | |
| $5.49 | -0.11 | -2.0% | $5.54 | $5.595 | $5.36 | 700,500 | |
| $5.60 | +0.02 | +0.4% | $5.56 | $5.715 | $5.43 | 1,220,800 | |
| $5.58 | -0.26 | -4.5% | $5.85 | $6.00 | $5.57 | 1,198,100 | |
| $5.84 | +0.47 | +8.8% | $5.39 | $5.87 | $5.31 | 1,555,700 | |
| $5.37 | -0.05 | -0.9% | $5.51 | $5.69 | $5.37 | 869,600 | |
| $5.42 | -0.11 | -2.0% | $5.53 | $5.55 | $5.27 | 648,500 | |
| $5.53 | +0.20 | +3.8% | $5.35 | $5.59 | $5.30 | 867,800 | |
| $5.33 | -0.16 | -2.9% | $5.32 | $5.52 | $5.193 | 1,202,900 | |
| $5.49 | -0.60 | -9.9% | $6.06 | $6.09 | $5.47 | 1,576,800 | |
| $6.09 | +0.12 | +2.0% | $6.09 | $6.21 | $5.85 | 1,024,500 | |
| $5.97 | +0.31 | +5.5% | $5.65 | $6.02 | $5.54 | 1,049,400 | |
| $5.66 | +0.005 | +0.1% | $5.56 | $5.885 | $5.42 | 2,486,600 | |
| $5.655 | -0.205 | -3.5% | $5.76 | $5.825 | $5.552 | 1,109,300 | |
| $5.86 | -0.64 | -9.8% | $6.55 | $6.65 | $5.85 | 1,595,400 | |
| $6.50 | -0.23 | -3.4% | $6.73 | $6.85 | $6.295 | 1,239,400 | |
| $6.73 | -0.11 | -1.6% | $7.02 | $7.09 | $6.54 | 1,843,600 | |
| $6.84 | +0.02 | +0.3% | $6.95 | $7.285 | $6.67 | 2,022,300 | |
| $6.82 | +0.28 | +4.3% | $6.64 | $7.42 | $6.52 | 3,356,700 | |
| $6.54 | +0.11 | +1.7% | $6.43 | $6.635 | $6.32 | 956,600 | |
| $6.43 | +0.36 | +5.9% | $6.03 | $6.48 | $5.85 | 976,900 | |
| $6.07 | -0.24 | -3.8% | $6.33 | $6.387 | $6.045 | 893,700 | |
| $6.31 | -0.05 | -0.8% | $6.34 | $6.40 | $6.00 | 1,428,700 | |
| $6.36 | -0.14 | -2.2% | $6.47 | $6.61 | $6.265 | 1,386,500 | |
| $6.50 | +0.39 | +6.4% | $6.20 | $6.54 | $6.10 | 1,459,300 | |
| $6.11 | +0.10 | +1.7% | $6.09 | $6.21 | $5.86 | 1,037,100 | |
| $6.01 | +0.16 | +2.7% | $5.86 | $6.215 | $5.80 | 7,400,000 | |
| $5.85 | -0.03 | -0.5% | $6.03 | $6.095 | $5.80 | 654,400 | |
| $5.88 | -0.09 | -1.5% | $6.00 | $6.12 | $5.78 | 742,700 | |
| $5.97 | -0.23 | -3.7% | $6.18 | $6.23 | $5.911 | 895,200 | |
| $6.20 | 0.00 | 0.0% | $6.21 | $6.265 | $6.085 | 821,900 | |
| $6.20 | +0.05 | +0.8% | $6.24 | $6.36 | $6.07 | 846,900 | |
| $6.15 | -0.18 | -2.8% | $6.21 | $6.345 | $6.10 | 1,171,900 | |
| $6.33 | -0.17 | -2.6% | $6.39 | $6.57 | $6.245 | 1,062,000 | |
| $6.50 | -0.29 | -4.3% | $6.80 | $6.86 | $6.47 | 1,002,700 | |
| $6.79 | -0.17 | -2.4% | $6.84 | $6.88 | $6.674 | 677,700 | |
| $6.96 | +0.05 | +0.7% | $6.96 | $7.045 | $6.83 | 563,900 | |
| $6.91 | +0.04 | +0.6% | $6.91 | $7.28 | $6.77 | 583,400 | |
| $6.87 | -0.14 | -2.0% | $6.90 | $7.06 | $6.76 | 639,600 | |
| $7.01 | -0.03 | -0.4% | $6.98 | $7.04 | $6.83 | 751,200 | |
| $7.04 | -0.61 | -8.0% | $7.55 | $7.59 | $7.035 | 623,100 | |
| $7.65 | -0.25 | -3.2% | $7.86 | $7.93 | $7.63 | 543,100 | |
| $7.90 | -0.16 | -2.0% | $8.03 | $8.04 | $7.79 | 581,600 | |
| $8.06 | +0.16 | +2.0% | $8.01 | $8.15 | $7.93 | 869,797 | |
| $7.90 | +0.37 | +4.9% | $7.66 | $8.02 | $7.50 | 2,055,160 | |
| $7.53 | +0.28 | +3.9% | $7.35 | $7.55 | $7.25 | 475,600 | |
| $7.25 | -0.41 | -5.4% | $7.56 | $7.56 | $7.24 | 419,700 |
- Ticker
- BOATS:STTK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BOATS
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest deck · Jun 9, 2026
Corporate Update (June 2026)
Corporate update · 25 slides
Latest news
Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 12, 2026
Closed $4.65 (-3.3%) on Nov 13, 2026
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 5, 2026
Closed $4.49 (-12.8%) on Nov 5, 2026
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026
Oct 13, 2026
Closed $5.49 (-9.9%) on Oct 13, 2026
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Oct 1, 2026
Closed $6.84 (+0.3%) on Oct 1, 2026
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
Sep 2, 2026
Closed $6.96 (+0.7%) on Sep 3, 2026
Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 11, 2026
Closed $7.18 (+0.6%) on Aug 11, 2026
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
Jun 10, 2026
Closed $4.13 (-3.3%) on Jun 10, 2026
Shattuck Labs, Inc. Announces Proposed Public Offering
Jun 9, 2026
Closed $4.13 (-3.3%) on Jun 10, 2026
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Jun 9, 2026
Closed $4.27 (+9.5%) on Jun 9, 2026
Shattuck Labs Announces Phase 1 Results for SL-325
Jun 8, 2026
Closed $3.90 (-14.8%) on Jun 8, 2026
Shattuck Labs, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 81 in all · newest Nov 12, 2026 · oldest 2020
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 9, 2023
- Decks
- 6 decks · latest Jun 9, 2026
Where Shattuck Labs, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:STTK · Home listing | NASDAQ | United States | USD |
| BOATS:STTK · This page | BOATS | United States | USD |
Valuation
Price/book 2.4× against a median of 2.2×: 6th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $260.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.10
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Shattuck Labs, Inc. · NASDAQ:STTK | US$454.2M | US$260.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.10 |
| Monopar Therapeutics Inc. · NASDAQ:MNPR | US$467.6M | US$362.8M | n/a | n/a | n/a | 3.7× | n/a | 0.0× | 1.18 |
| BlossomHill Therapeutics, Inc. · NASDAQ:BLSM | US$461.2M | US$259.4M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | n/a |
| Neurogene Inc. · NASDAQ:NGNE | US$458.5M | US$106.4M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.47 |
| Assembly Biosciences, Inc. · NASDAQ:ASMB | US$454.4M | US$142.3M | n/a | 2.1× | n/a | 1.5× | −16.6% | 0.0× | 1.00 |
| G2GBIO, Inc. · KRX:456160 | US$449.1M | US$289.0M | n/a | 176× | n/a | 4.3× | −793.7% | 0.0× | n/a |
| DiaMedica Therapeutics Inc. · NASDAQ:DMAC | US$445.1M | US$410.4M | n/a | n/a | n/a | 15.5× | n/a | 0.0× | 1.67 |
| CytomX Therapeutics, Inc. · NASDAQ:CTMX | US$442.5M | US$98.96M | n/a | 7.0× | n/a | 1.6× | −609.0% | 0.0× | 1.21 |
| Capricor Therapeutics, Inc. · NASDAQ:CAPR | US$441.3M | US$335.9M | n/a | n/a | n/a | 2.1× | n/a | 0.4× | 0.94 |
| Hansa Biopharma AB · OMXSTO:HNSA | US$440.9M | US$488.0M | n/a | 26.3× | n/a | n/a | −406.5% | n/a | n/a |
| Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373 | US$439.3M | US$408.1M | n/a | 16.2× | n/a | 19.4× | −57.0% | 0.9× | n/a |
| Median of the others | US$447.1M | US$312.5M | 16.2× | 2.2× | −406.5% | 0.0× | 1.19 |
Forecasts
9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.55 · 11 analysts
- Revenue, year to Dec 2026
- 122.2K · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Taylor H. Schreiber | Chief Executive Officer, and Co-founder |
| Andrew R. Neill | Chief Financial Officer |
| Clay Siegall | President, Chairman of the Board of Immunome, Inc. |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer |
| Amy Franke | Vice President of Clinical Operations |
| Brad Huckabee | Vice President of Accounting and SEC reporting |
| George Golumbeski | Chairman of the Board and Former Executive Vice President of Business Development for Celgene |
| Kelli Collin | Senior Vice President of Quality |
| Michael Choi | Vice President of Clinical Development |
| Philip Jackson | Vice President of FP&A |
| Shoba Ravichandran | Senior Vice President of Clinical Development |
| Thomas Lampkin | Senior Vice President of Regulatory Affairs |
| Abhinav A. Shukla | Chief Technical Officer |
| Casi DeYoung | Chief Business Officer |
| Lini Pandite | Chief Medical Officer |
| Suresh de Silva | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| George Golumbeski | Chairman of the Board and Former Executive Vice President of Business Development for Celgene |
| Taylor H. Schreiber | Chief Executive Officer, and Co-founder |
Events
- Next results
- Mar 11, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Shattuck Labs (NASDAQ:STTK) Q3 2023 Earnings Call | Thu, Nov 09, 2023 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −12.8% |
| Q2 2026 | Aug 11, 2026 · Before open | +0.6% |
| Q1 2026 | May 7, 2026 · Before open | −6.3% |
| Q4 2025 | Mar 17, 2026 | +0.3% |
| Q3 2025 | Nov 6, 2025 · After close | +1.0% |
| Q2 2025 | Aug 14, 2025 · Before open | +6.0% |
| Q1 2025 | Apr 30, 2025 · Before open | +19.0% |
| Q4 2024 | Mar 27, 2025 · Before open | −3.4% |
| Q3 2024 | Nov 14, 2024 · Before open | +12.3% |
| Q2 2024 | Aug 1, 2024 · After close | −3.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | +2.2% |
| Q4 2023 | Feb 29, 2024 · After close | +10.5% |
| Q3 2023 | Nov 9, 2023 · Before open | −23.2% |
| Q2 2023 | Aug 10, 2023 · After close | −2.3% |
| Q1 2023 | May 9, 2023 · After close | −2.1% |
| Q4 2022 | Feb 23, 2023 · After close | +0.4% |
| Q3 2022 | Nov 8, 2022 · After close | −5.9% |
| Q2 2022 | Aug 11, 2022 · Before open | −4.4% |
| Q1 2022 | May 12, 2022 · Before open | +8.3% |
| Q4 2021 | Mar 15, 2022 · Before open | +3.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (June 2026) | Corporate update | 25 slides | Jun 9, 2026 |
| Investor Presentation (November 2025) | Investor deck | 30 slides | Nov 6, 2025 |
| European Crohn's and Colitis Organization 2025 | Conference | 9 slides | Feb 20, 2025 |
| 3rd Gamma Delta T Therapy Summit 2022 | Conference | 28 slides | Jul 27, 2022 |
| TIGIT Therapies Digital Summit 2021 | Conference | 30 slides | Dec 9, 2021 |
| SITC 2021 Annual Meeting Investor Conference Call & Webcast | Conference | 44 slides | Nov 12, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock and pre-funded warrants Update: about US$75M · US$4 a share · Leerink Partners +3 Dealers: Leerink Partners (co-lead), J.P. Morgan (co-lead), Piper Sandler (co-lead), Cantor (co-lead) | Jun 10, 2026 |
| Warrant exercise of common stock warrants Announced: about US$54.9M | Jun 9, 2026 |
| Private placement of common stock and common stock warrants Closed: US$103M raised · US$0.8677 a share · Warrants at US$1.0846 · Wedbush & Co., LLC Dealers: Wedbush & Co., LLC (lead) Buyers: OrbiMed (led the private placement); Coastlands Capital; Prosight Capital; Adage Capital; Redmile Group; NextBio Capital Use of proceeds: Fund operations into 2029 and advance SL-325 through clinical milestones, including randomized Phase 2 trials | Aug 26, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$17.00 a share on Oct 8, 2020.
- Price
- US$17.00 a share
- Shares offered
- 11,882,352 shares of common stock
- Offering size
- US$202 million
- Underwriters' option
- Up to 1,782,352 more shares
- Underwriters
- Citigroup, Cowen, Evercore ISI, Needham & Company · In the order on the cover
- Shares delivered
- On or about Oct 14, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 7, 2020 |
| Filed publicly | Sep 18, 2020 |
| Amended twice | Newest Oct 8, 2020 |
| Shares registered with an exchange | Oct 5, 2020 |
| Declared effective by the SEC | Oct 8, 2020 |
| Final prospectus, with the price | Oct 13, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 13, 2020 |
| EFFECT · Notice that a registration is effective | Oct 8, 2020 |
| S-1MEF · Registration of more shares for the same offering | Oct 8, 2020 |
| CERT · Exchange's certificate of listing | Oct 8, 2020 |
| S-1/A · Registration statement, amended | Oct 8, 2020 |
| CORRESP · Letter to the SEC | Oct 7, 2020 |
| UPLOAD · Letter from the SEC | Oct 7, 2020 |
| CORRESP · Letter to the SEC | Oct 6, 2020 |
| CORRESP · Letter to the SEC | Oct 6, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 5, 2020 |
All 20 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Oct 5, 2020 |
| CORRESP · Letter to the SEC | Oct 5, 2020 |
| UPLOAD · Letter from the SEC | Oct 1, 2020 |
| CORRESP · Letter to the SEC | Sep 25, 2020 |
| UPLOAD · Letter from the SEC | Sep 22, 2020 |
| S-1 · Registration statement | Sep 18, 2020 |
| DRS/A · Draft registration statement, amended | Sep 10, 2020 |
| DRSLTR · Letter to the SEC with a draft | Sep 10, 2020 |
| UPLOAD · Letter from the SEC | Sep 3, 2020 |
| DRS · Draft registration statement | Aug 7, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 13, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.00M | 5.72M | 1.66M | 652.0K | 30.0M | 9.93M | 9.89M | 22.4M |
| Cost of revenue | 2.95M | 4.89M | 4.04M | 3.38M | 1.38M | 37.5M | 29.2M | 24.8M |
| Gross profit | -1.95M | 827.0K | -2.38M | 652.0K | 28.6M | 9.93M | -19.3M | -2.37M |
| Research and development | 35.3M | 67.2M | 74.3M | 82.9M | 56.6M | 37.5M | 29.2M | 24.8M |
| Selling, general and administrative | 17.2M | 19.1M | 19.3M | 21.1M | 18.7M | 9.38M | 5.74M | 3.78M |
| Operating income | -51.5M | -80.6M | -92.0M | -103.3M | -45.3M | -36.9M | -25.1M | -6.15M |
| Depreciation and amortization | 3.70M | 3.80M | 4.00M | 3.10M | 1.40M | 600.0K | 500.0K | 255.0K |
| EBITDA | -47.8M | -76.8M | -88.0M | -100.2M | -43.9M | -36.3M | -24.6M | -5.89M |
| Interest expense | 3.07M | 1.38M | 0 | 0 | 2.63M | |||
| Income before tax | -48.8M | -75.4M | -87.3M | -101.9M | -45.0M | -36.6M | -24.0M | -7.39M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.39M |
| Net income | -48.8M | -75.4M | -87.3M | -101.9M | -45.0M | -36.6M | -24.0M | -7.39M |
| Earnings per share, basic | -0.70 | -1.49 | -2.05 | -2.41 | -1.07 | -2.36 | -3.17 | -0.49 |
| Earnings per share, diluted | -0.70 | -1.49 | -2.05 | -2.41 | -1.07 | -2.36 | -3.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 54.2M | 57.4M | 125.6M | 47.4M | 92.3M | 157.9M | 7.01M | 31.6M |
| Short-term investments | 23.9M | 15.6M | 5.00M | 113.9M | 176.5M | 177.6M | 32.1M | 28.7M |
| Receivables | 3.07M | 381.0K | 2.60M | |||||
| Current assets | 82.5M | 79.2M | 143.2M | 184.6M | 288.3M | 345.6M | 42.4M | 65.6M |
| Property, plant and equipment | 6.11M | 9.81M | 13.8M | 17.7M | 9.94M | 3.00M | 2.44M | 2.50M |
| Total assets | 91.0M | 91.0M | 159.6M | 205.3M | 298.6M | 349.0M | 45.0M | 68.2M |
| Accounts payable | 2.10M | 2.42M | 1.59M | 7.17M | 10.0M | 1.75M | 3.05M | 2.05M |
| Current liabilities | 7.05M | 8.92M | 11.5M | 25.0M | 24.6M | 16.8M | 20.0M | 20.9M |
| Total debt | 2.42M | 3.41M | 4.20M | 4.90M | ||||
| Total liabilities | 8.64M | 11.4M | 14.9M | 29.2M | 26.8M | 39.1M | 30.5M | 79.2M |
| Shareholders' equity | 82.4M | 79.6M | 144.7M | 176.2M | 271.8M | 309.9M | -34.5M | -11.1M |
| Shares outstanding | 63.3M | 47.7M | 47.3M | 42.4M | 42.3M | 41.8M | 7.60M | 15.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -39.9M | -60.5M | -81.2M | -94.5M | -57.1M | -33.7M | -21.0M | -6.90M |
| Capital spending | -71.0K | -59.0K | -407.0K | -11.6M | -7.93M | -727.0K | -470.0K | -1.18M |
| Free cash flow | -40.0M | -60.6M | -81.6M | -106.1M | -65.0M | -34.4M | -21.4M | -8.08M |
| Cash from investing | -7.89M | -8.51M | 110.9M | 49.4M | -10.4M | -146.3M | -3.59M | -29.9M |
| Cash from financing | 44.6M | 787.0K | 48.6M | 171.0K | 1.93M | 330.9M | -64.0K | 35.1M |
| Share buybacks | -17.0K | -53.0K | 171.0K | 1.93M | 213.2M | |||
| Change in cash | -3.19M | -68.2M | 78.2M | -44.9M | -65.6M | 150.9M | -24.6M | -1.68M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 17, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 11, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 11, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Jun 9, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 2, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 8, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 22, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 22, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 22, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 16, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jan 13, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Nov 6, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 424B3 · Prospectus | Sep 29, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 29, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 24, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 18, 2025 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 2, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 26, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 26, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 6, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 5, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 15, 2025 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | May 21, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 21, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 21, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 1, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Results | SEC |
| 10-K/A · Annual report, amended | May 1, 2025 | Annual report | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Mar 27, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 6, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 4, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Aug 16, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 1, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2024 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Jun 11, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 10, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 2, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 2, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 23, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 8, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 4, 2024 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Feb 29, 2024 | Offer document | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| 8-K · Current report | Feb 13, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 2, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2024 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 30, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| S-3 · Registration statement | Jan 24, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 10, 2024 | Other filings | SEC |
This page holds 200 of 415 filings. Open Filings
Cap table
Built by 6ix from Shattuck Labs, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 101,842,552
- Fully diluted
- 102,226,552
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 101,842,552 | Nov 2, 2026 |
| Options and RSUs | 384,000 | Nov 10, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.08 · expiry not stated |
| Stock options · US$4.85 · expire about Nov 2036 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 101,842,552 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jeremy Green Other companies: Atara Biotherapeutics, Inc. (Director · Since at least May 16, 2025); Fate Therapeutics, Inc. (Director · Since at least Dec 15, 2017); LifeSci Acquisition II Corp (Director · Oct 6, 2021 – May 11, 2023 · Past); Absci Corporation (Director · Jul 21, 2021 – Jun 12, 2024 · Past); Medavail Holdings Inc (Director · Nov 17, 2020 – Jun 16, 2023 · Past); Augmedix Inc (Director · Oct 5, 2020 – Oct 2, 2024 · Past); IGM Biosciences Inc (Director · Sep 17, 2019 – Mar 31, 2025 · Past); Alder BioPharmaceuticals Inc (Director · Apr 25, 2018 – Oct 22, 2019 · Past) | Director · Since at least Oct 8, 2020 |
| Clay Siegall Other companies: Tourmaline Bio Inc. (Director · Since at least Dec 13, 2023); Immunome, Inc. (President & Chief Executive Officer · Since at least Oct 2, 2023); Nurix Therapeutics, Inc. (Director · May 28, 2021 – May 5, 2022 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 22, 2019 · Past); Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Aug 7, 2020 · Past); Seagen Inc (President & CEO, Director · Jan 31, 2006 – May 12, 2022 · Past) | President, Chairman of the Board of Immunome, Inc. · Since at least Mar 1, 2024 |
| George Golumbeski Other companies: Acumen Pharmaceuticals, Inc. (Chairman of its Board of Directors · Since at least Nov 6, 2025); Mural Oncology plc (Director · Since at least Jul 30, 2024); Sage Therapeutics Inc (Director · Since at least Jan 22, 2019); Corbus Pharmaceuticals Holdings, Inc. (Director · Jul 6, 2020 – Jul 6, 2020 · Past); Enanta Pharmaceuticals, Inc. (Director · Feb 7, 2014 – Feb 26, 2020 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past) | Director · Since at least Oct 8, 2020 |
| Helen M. Boudreau Other companies: Rallybio Corporation (Board Member · Since at least Jul 29, 2021); Tvardi Therapeutics, Inc. (Director · Aug 2, 2023 – Jun 4, 2024 · Past); Kineta Inc. (Chief Financial Officer · Feb 10, 2016 – Mar 1, 2018 · Past) | Director · Since at least Oct 8, 2020 |
| Neil Gibson Other companies: Instil Bio, Inc. (Board Member · Since at least Mar 18, 2021); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Jun 1, 2023 · Past); Regulus Therapeutics Inc (Chief Scientific Officer · Oct 4, 2012 – Jan 28, 2015 · Past) | Director · Since at least Oct 8, 2020 |
| Daniel Baker Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Jan 28, 2025); Cue Biopharma, Inc. (CHIEF DEVELOPMENT OFFICER · Since at least Nov 25, 2024) | Director · Since at least Aug 25, 2025 |
| Michael Lee Other companies: IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Fate Therapeutics, Inc. (Board Member · Since at least Jul 31, 2018) | Director · Since at least Oct 8, 2020 |
| Mona Ashiya Other companies: Disc Medicine, Inc. (Director · Since at least Dec 29, 2022); Sierra Oncology Inc (Director · Jun 8, 2021 – Jul 1, 2022 · Past) | Director · Since at least Aug 25, 2025 |
| Arundathy N Pandite Other companies: Codiak BioSciences Inc (Director · Aug 16, 2021 – Jun 17, 2022 · Past) | Chief Medical Officer · Since at least Oct 8, 2020 |
| Carrie Brownstein Other companies: Zentalis Pharmaceuticals, Inc. (Chief Medical Officer · Oct 3, 2022 – Oct 4, 2023 · Past) | Director · Since at least Oct 22, 2021 |
All 29 people
| Person | Seat |
|---|---|
| Casi DeYoung Other companies: Synlogic Inc (Chief Business Officer · Sep 30, 2015 – Mar 11, 2016 · Past) | Chief Business Officer · Since at least Oct 8, 2020 |
| Abhinav A. Shukla | Chief Technical Officer · Since at least Apr 7, 2022 |
| Amy Franke | Vice President of Clinical Operations · Since at least Nov 4, 2026 |
| Amy Kate Sasser | Director · Since at least Mar 1, 2024 |
| Andrew R. Neill | Chief Financial Officer · Since at least Oct 8, 2020 |
| Brad Huckabee | Vice President of Accounting and SEC reporting · Since at least Nov 4, 2026 |
| Erin Ator Thomson | General Counsel · Oct 8, 2020 – Jan 25, 2023 · Past |
| Josiah Hornblower | Director · Oct 8, 2020 – Jul 15, 2021 · Past |
| Kelli Collin | Senior Vice President of Quality · Since at least Nov 4, 2026 |
| Lini Pandite | Chief Medical Officer · Since at least Jun 5, 2026 |
| Michael Choi | Vice President of Clinical Development · Since at least Jun 5, 2026 |
| Philip Jackson | Vice President of FP&A · Since at least Nov 4, 2026 |
| Shoba Ravichandran | Senior Vice President of Clinical Development · Since at least Oct 1, 2026 |
| Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer · Since at least Mar 23, 2023 |
| Suresh de Silva | Chief Scientific Officer · Since at least Oct 13, 2026 |
| Taylor H. Schreiber | Chief Executive Officer, and Co-founder · Since at least Oct 8, 2020 |
| Thomas Lampkin | Senior Vice President of Regulatory Affairs · Since at least Nov 4, 2026 |
| Tyler Brous | Director · Since at least Oct 8, 2020 |
| Victor Stone | Director · Oct 8, 2020 – Oct 8, 2020 · Past |
Log in to ask 6ix AI your own questions about Shattuck Labs, Inc.